<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03989323</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0816</org_study_id>
    <nct_id>NCT03989323</nct_id>
  </id_info>
  <brief_title>A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE</brief_title>
  <acronym>IMMUCARE-BASE</acronym>
  <official_title>A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The number of patients affected by cancer and treated with immunotherapy is continuously
      increasing. With the advent of these new therapies, the investigators observe the emergence
      of new and unexpected toxicities. The care of patients treated with these molecules require
      the development of multidisciplinary skills and the introduction of a professional network
      capable of taking care of immunotherapy related toxicity (irAE) that can affect different
      organs and for which immediate and effective interventions are necessary for patient
      survival.

      IMMUCARE-BASE will comprehensively enable the collection, of clinical and biological data of
      patients treated with anticancer immunotherapy. The creation of this database is essential to
      identify clinico-biological factors predisposing to toxicity, and to define the best
      strategies to prevent the early onset of irAE and/or to treat them. Ultimately, the objective
      of this database is to collect enough data to be able to personalise in the future the
      immunotherapy treatment according to the benefits and to anticipate risks for each patient.

      The objective of the biological collection is to perform ancillary studies for understanding
      mechanism leading to toxicity and for the development of research programs in the field of
      immunotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">June 2029</completion_date>
  <primary_completion_date type="Anticipated">June 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimation of the incidence of immunotherapy-related toxicities (all grades, of all organs, in real life) in patients treated for the first time with anticancer immunotherapy and enrolled in the &quot;IMMUCARE-BASE&quot; clinical database</measure>
    <time_frame>10 years</time_frame>
    <description>Patients can be treated with immunotherapy alone, or in association with other immunotherapies, or association with chemotherapies, targeted therapies or radiotherapy. It will include all types of cancers that can be treated with immunotherapy, also including patients that are in clinical trials.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Patients treated with immunotherapy</arm_group_label>
    <description>Patients receiving for the first time an immunotherapy treatment for their cancer (Checkpoints inhibitors, such as PD-1 or PD-L1 or CTLA4…). Patients will be enrolled before starting the immunotherapy treatment and will be followed up for 5 years or until the permanent discontinuation of the immunotherapy treatment to describe the arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Estimation of the incidence of the irAE</intervention_name>
    <description>Assessment of the incidence of the irAE in patients treated with immunotherapy at the Hospices Civils de Lyon (irAE of all grades and from all organs) and creation of a biological collection of blood, plasma, serum and PBMCs from patients before treatment, under treatment and at the onset of irAEs.</description>
    <arm_group_label>Patients treated with immunotherapy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood samples (36 mL) will be collected at the time of the first and second
      immunotherapy administrations, during routine care. In the case of grade 3 or 4 toxicities,
      blood samples will be collected as well at the time of irAE onset.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with cancer and starting anticancer immunotherapy (-immune checkpoint
        inhibitors: anti-PD-1, anti-PD-L1, anti-CTLA4, anti-Lag-3, anti-Tim-3, anti-TIGIT or other
        new emerging immune checkpoint inhibitors).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18

          -  Patient starting anticancer immunotherapy treatment(immune checkpoint inhibitors like
             anti-PD-1, anti-PD-L1, anti-CTLA4, anti-Lag-3, anti-Tim-3, anti-TIGIT or other new
             anticancer immunotherapy) in monotherapy or associatied with other anticancer
             molecules.

          -  Patient who had already received immunotherapy can be eligible to IMMUCARE-BASE
             provided that the last immunotherapy treatment had been administered &gt; 6 months ago.

          -  Patient who received written information about IMMUCARE-BASE.

          -  Patient receiving immunotherapy as a part of a clinical trial can be eligible to
             IMMUCARE-BASE according to the indications given by the promoter of this trial.

          -  Patient in a clinical trial which includes a combination of therapy with one of the
             drugs administered in a blind manner vs placebo, can be eligible to IMMUCARE-BASE
             provided that (i) the treatment administered in a blind manner is not the
             immunotherapy and (ii) the clinical trial allows concomitant participation of a
             patient in another non-interventional study.

          -  A Patient that has been already included in IMMUCARE-BASE and who terminates the study
             because of a change of treatment, can be included again in IMMUCARE-BASE if he/she
             agrees and provided that (i) is the new treatment includes immunotherapy (alone or in
             association with other anticancer molecules) and (iii) the new immunotherapy treatment
             is administered after 6 months from the last administration of the previous
             immunotherapy.

        Inclusion criteria specific to the biological collection:

        -Signature of the informed consent.

        Exclusion Criteria:

          -  Patient who had received immunotherapy within 6 months before entering in
             IMMUCARE-BASE

          -  Minor patient

          -  Pregnant women

          -  Patient under juridical protection

          -  Patient refusal to participate.

        Exclusion criteria for the biological collection:

          -  Weight ≤ 50kg

          -  Haemoglobin &lt; 90g/L at the time of the inclusion

          -  Patient participating in clinical trials where blood samples are taken for ancillary
             studies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan LOPEZ, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan LOPEZ, MD</last_name>
    <phone>+33 4 78 86 16 07</phone>
    <phone_ext>+33</phone_ext>
    <email>jonathan.lopez@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara CALATTINI, PhD</last_name>
    <phone>+33 4.78.86.37.79</phone>
    <phone_ext>+33</phone_ext>
    <email>sara.calattini@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital L. Pradel</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sara Calattini, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Michael DURUISSEAUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerald RAVEROT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juliette ABEILLON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sara Calattini, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jerome HONNORAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bastien JOUBERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sara Calattini, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Lize KIAKOUAMA-MALEKA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe CERUSE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amandine BRUYAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fanny LEBOSSE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe MERLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francois BAILLY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabien ZOULIM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital E Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sara Calattini, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas WALTER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine LOMBARD-BOHAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier LYON SUD</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jonathan LOPEZ, MD</last_name>
      <phone>+33 4 78 86 16 07</phone>
      <phone_ext>+33</phone_ext>
      <email>jonathan.lopez@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sara CALATTINI, PhD</last_name>
      <phone>+33 4.78.86.37.79</phone>
      <phone_ext>+33</phone_ext>
      <email>sara.calattini@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Stéphane DALLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc THOMAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mona AMINI-ADL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien DEBARBIEUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas POULALHON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie PERIER-MUZET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Jean SOUQUET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien COURAUD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie FREYMOND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clara DELARUELLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles BOSCHETTI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion CHAUVENET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane NANCEY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis MAILLET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien PERON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoit YOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles FREYER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique TRILLET-LENOIR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie BONNIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie TARTAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salima HAMIZI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amandine BRUYAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivia LE SAUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie DUPLOMB, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe SAJOUS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire FALANDRY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cyril CONFAVREUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel BACHY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles SALLES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lionel KARLIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hervé GHESQUIERES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine CUGNET-ANCEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles THIVOLET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien VOUILLARMET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 14, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>June 17, 2019</last_update_submitted>
  <last_update_submitted_qc>June 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

